Merging DBS with viral vector or stem cell implantation: “hybrid” stereotactic surgery as an evolution in the surgical treatment of Parkinson's disease

Molecular Therapy Methods and Clinical Development

Volumn 3, Issue , 2016, Pages 15051-

  Rowland, Nathan C ^a   Kalia, Suneil K ^b   Kalia, Lorraine V ^b,c   Larson, Paul S ^a   Lim, Daniel A ^a   Bankiewicz, Krystof S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; VIRUS VECTOR;

BRAIN DEPTH STIMULATION; DOPAMINERGIC NERVE CELL; FETUS CELL; HUMAN; MOLECULAR BIOLOGY; NEUROIMAGING; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEM CELL TRANSPLANTATION; STEREOTAXIC SURGERY; VIRAL GENE THERAPY; CENTRAL NERVOUS SYSTEM; DOPAMINERGIC ACTIVITY; GENE THERAPY; HYBRID; IMPLANTATION; STEM CELL;

EID: 84994868860     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1038/mtm.2015.51     Document Type: Review

References (118)

1. 1 Braak, H, Braak, E, Pathoanatomy of Parkinson's disease. J Neurol 247:suppl. 2 (2000), II3–I10.
2. 2 Foltynie, T, Brayne, C, Barker, RA, The heterogeneity of idiopathic Parkinson's disease. J Neurol 249 (2002), 138–145.
3. 3 Hughes, AJ, Daniel, SE, Ben-Shlomo, Y, Lees, AJ, The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125 (2002), 861–870.
4. 4 Beach, TG, Adler, CH, Lue, L, Sue, LI, Bachalakuri, J, Henry-Watson, J, et al., Arizona Parkinson's Disease Consortium, Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol 117 (2009), 613–634.
5. 5 Kalia, LV, Lang, AE, Parkinson's disease. Lancet 386 (2015), 896–912.
6. 6 Gaig, C, Tolosa, E, When does Parkinson's disease begin?. Mov Disord 24:suppl. 2 (2009), S656–S664.
7. 7 Kalia, LV, Kalia, SK, Lang, AE, Disease-modifying strategies for Parkinson's disease. Mov Disord 30 (2015), 1442–1450.
8. 8 Freed, CR, Greene, PE, Breeze, RE, Tsai, WY, DuMouchel, W, Kao, R, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344 (2001), 710–719.
9. 9 Olanow, CW, Goetz, CG, Kordower, JH, Stoessl, AJ, Sossi, V, Brin, MF, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 54 (2003), 403–414.
10. 10 Annett, LE, Torres, EM, Ridley, RM, Baker, HF, Dunnett, SB, A comparison of the behavioural effects of embryonic nigral grafts in the caudate nucleus and in the putamen of marmosets with unilateral 6-OHDA lesions. Exp Brain Res 103 (1995), 355–371.
11. 11 Björklund, A, Stenevi, U, Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants. Brain Res 177 (1979), 555–560.
12. 12 Dunnett, SB, Björklund, A, Stenevi, U, Iversen, SD, Behavioural recovery following transplantation of substantia nigra in rats subjected to 6-OHDA lesions of the nigrostriatal pathway. I. Unilateral lesions. Brain Res 215 (1981), 147–161.
13. 13 Kirik, D, Winkler, C, Björklund, A, Growth and functional efficacy of intrastriatal nigral transplants depend on the extent of nigrostriatal degeneration. J Neurosci 21 (2001), 2889–2896.
14. 14 Lee, CS, Cenci, MA, Schulzer, M, Björklund, A, Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain 123 (2000), 1365–1379.
15. 15 Olanow, CW, Kordower, JH, Freeman, TB, Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci 19 (1996), 102–109.
16. 16 Perlow, MJ, Freed, WJ, Hoffer, BJ, Seiger, A, Olson, L, Wyatt, RJ, Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Science 204 (1979), 643–647.
17. 17 Redmond, DE, Sladek, JR Jr, Roth, RH, Collier, TJ, Elsworth, JD, Deutch, AY, et al. Fetal neuronal grafts in monkeys given methylphenyltetrahydropyridine. Lancet 1 (1986), 1125–1127.
18. 18 Wuerthele, SM, Freed, WJ, Olson, L, Morihisa, J, Spoor, L, Wyatt, RJ, et al. Effect of dopamine agonists and antagonists on the electrical activity of substantia nigra neurons transplanted into the lateral ventricle of the rat. Exp Brain Res 44 (1981), 1–10.
19. 19 Ma, Y, Feigin, A, Dhawan, V, Fukuda, M, Shi, Q, Greene, P, et al. Dyskinesia after fetal cell transplantation for parkinsonism: a PET study. Ann Neurol 52 (2002), 628–634.
20. 20 Brundin, P, Pogarell, O, Hagell, P, Piccini, P, Widner, H, Schrag, A, et al. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain 123 (2000), 1380–1390.
21. 21 Defer, GL, Geny, C, Ricolfi, F, Fenelon, G, Monfort, JC, Remy, P, et al. Long-term outcome of unilaterally transplanted parkinsonian patients. I. Clinical approach. Brain 119 (1996), 41–50.
22. 22 Freed, CR, Breeze, RE, Rosenberg, NL, Schneck, SA, Kriek, E, Qi, JX, et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. N Engl J Med 327 (1992), 1549–1555.
23. 23 Freed, CR, Breeze, RE, Rosenberg, NL, Schneck, SA, Wells, TH, Barrett, JN, et al. Transplantation of human fetal dopamine cells for Parkinson's disease. Results at 1 year. Arch Neurol 47 (1990), 505–512.
24. 24 Hagell, P, Schrag, A, Piccini, P, Jahanshahi, M, Brown, R, Rehncrona, S, et al. Sequential bilateral transplantation in Parkinson's disease: effects of the second graft. Brain 122 (1999), 1121–1132.
25. 25 Hauser, RA, Freeman, TB, Snow, BJ, Nauert, M, Gauger, L, Kordower, JH, et al. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch Neurol 56 (1999), 179–187.
26. 26 Kish, SJ, Shannak, K, Hornykiewicz, O, Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 318 (1988), 876–880.
27. 27 Kordower, JH, Freeman, TB, Snow, BJ, Vingerhoets, FJ, Mufson, EJ, Sanberg, PR, et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 332 (1995), 1118–1124.
28. 28 Kordower, JH, Rosenstein, JM, Collier, TJ, Burke, MA, Chen, EY, Li, JM, et al. Functional fetal nigral grafts in a patient with Parkinson's disease: chemoanatomic, ultrastructural, and metabolic studies. J Comp Neurol 370 (1996), 203–230.
29. 29 Lindvall, O, Brundin, P, Widner, H, Rehncrona, S, Gustavii, B, Frackowiak, R, et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 247 (1990), 574–577.
30. 30 Lindvall, O, Widner, H, Rehncrona, S, Brundin, P, Odin, P, Gustavii, B, et al. Transplantation of fetal dopamine neurons in Parkinson's disease: one-year clinical and neurophysiological observations in two patients with putaminal implants. Ann Neurol 31 (1992), 155–165.
31. 31 Lindvall, O, Sawle, G, Widner, H, Rothwell, JC, Björklund, A, Brooks, D, et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann Neurol 35 (1994), 172–180.
32. 32 Mendez, I, Dagher, A, Hong, M, Hebb, A, Gaudet, P, Law, A, et al. Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line–derived neurotrophic factor in patients with Parkinson's disease. Report of two cases and technical considerations. J Neurosurg 92 (2000), 863–869.
33. 33 Mendez, I, Dagher, A, Hong, M, Gaudet, P, Weerasinghe, S, McAlister, V, et al. Simultaneous intrastriatal and intranigral fetal dopaminergic grafts in patients with Parkinson disease: a pilot study. Report of three cases. J Neurosurg 96 (2002), 589–596.
34. 34 Peschanski, M, Defer, G, N'Guyen, JP, Ricolfi, F, Monfort, JC, Remy, P, et al. Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon. Brain 117 (1994), 487–499.
35. 35 Spencer, DD, Robbins, RJ, Naftolin, F, Marek, KL, Vollmer, T, Leranth, C, et al. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. N Engl J Med 327 (1992), 1541–1548.
36. 36 Widner, H, Tetrud, J, Rehncrona, S, Snow, B, Brundin, P, Gustavii, B, et al. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). N Engl J Med 327 (1992), 1556–1563.
37. 37 Lindvall, O, Björklund, A, Cell therapy in Parkinson's disease. NeuroRx 1 (2004), 382–393.
38. 38 Kordower, JH, Chu, Y, Hauser, RA, Freeman, TB, Olanow, CW, Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 14 (2008), 504–506.
39. 39 Li, JY, Englund, E, Widner, H, Rehncrona, S, Björklund, A, Lindvall, O, et al. Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease. Mov Disord 25 (2010), 1091–1096.
40. 40 Dehay, B, Vila, M, Bezard, E, Brundin, P, Kordower, JH, Alpha-synuclein propagation: New insights from animal models. Mov Disord, 2015 (epub ahead of print).
41. 41 Kim, JH, Auerbach, JM, Rodríguez-Gómez, JA, Velasco, I, Gavin, D, Lumelsky, N, et al. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature 418 (2002), 50–56.
42. 42 Braak, H, Del Tredici, K, Rüb, U, de Vos, RA, Jansen Steur, EN, Braak, E, Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24 (2003), 197–211.
43. 43 Bernheimer, H, Birkmayer, W, Hornykiewicz, O, Jellinger, K, Seitelberger, F, Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20 (1973), 415–455.
44. 44 Kordower, JH, Freeman, TB, Chen, EY, Mufson, EJ, Sanberg, PR, Hauser, RA, et al. Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease. Mov Disord 13 (1998), 383–393.
45. 45 Dunnett, SB, Robbins, TW, The functional role of mesotelencephalic dopamine systems. Biol Rev Camb Philos Soc 67 (1992), 491–518.
46. 46 Fujita, KA, Ostaszewski, M, Matsuoka, Y, Ghosh, S, Glaab, E, Trefois, C, et al. Integrating pathways of Parkinson's disease in a molecular interaction map. Mol Neurobiol 49 (2014), 88–102.
47. 47 Bjorklund, LM, Sánchez-Pernaute, R, Chung, S, Andersson, T, Chen, IY, McNaught, KS, et al. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci USA 99 (2002), 2344–2349.
48. 48 Isacson, O, Bjorklund, LM, Schumacher, JM, Toward full restoration of synaptic and terminal function of the dopaminergic system in Parkinson's disease by stem cells. Ann Neurol 53:suppl. 3 (2003), S135–S146.
49. 49 Lindvall, O, Kokaia, Z, Martinez-Serrano, A, Stem cell therapy for human neurodegenerative disorders-how to make it work. Nat Med 10 (2004), S42–S50.
50. 50 Soldner, F, Laganière, J, Cheng, AW, Hockemeyer, D, Gao, Q, Alagappan, R, et al. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell 146 (2011), 318–331.
51. st century: can stem cell transplantation compete?. J Comp Neurol 522 (2014), 2802–2816.
52. 52 Barker, RA, Drouin-Ouellet, J, Parmar, M, Cell-based therapies for Parkinson disease'past insights and future potential. Nat Rev Neurol 11 (2015), 492–503.
53. 53 Bankiewicz, KS, Eberling, JL, Kohutnicka, M, Jagust, W, Pivirotto, P, Bringas, J, et al. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol 164 (2000), 2–14.
54. 54 Kirik, D, Georgievska, B, Burger, C, Winkler, C, Muzyczka, N, Mandel, RJ, et al. Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer. Proc Natl Acad Sci USA 99 (2002), 4708–4713.
55. 55 Bankiewicz, KS, Forsayeth, J, Eberling, JL, Sanchez-Pernaute, R, Pivirotto, P, Bringas, J, et al. Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther 14 (2006), 564–570.
56. 56 Eberling, JL, Jagust, WJ, Christine, CW, Starr, P, Larson, P, Bankiewicz, KS, et al. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 70 (2008), 1980–1983.
57. 57 Christine, CW, Starr, PA, Larson, PS, Eberling, JL, Jagust, WJ, Hawkins, RA, et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 73 (2009), 1662–1669.
58. 58 Lim, ST, Airavaara, M, Harvey, BK, Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS. Pharmacol Res 61 (2010), 14–26.
59. 59 Björklund, T, Carlsson, T, Cederfjäll, EA, Carta, M, Kirik, D, Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's disease. Brain 133 (2010), 496–511.
60. 60 Marks, WJ Jr, Bartus, RT, Siffert, J, Davis, CS, Lozano, A, Boulis, N, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 9 (2010), 1164–1172.
61. 61 Warren Olanow, C, Bartus, RT, Baumann, TL, Factor, S, Boulis, N, Stacy, M, et al. Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: a double-blind, randomized, controlled trial. Ann Neurol 78 (2015), 248–257.
62. 62 Luo, J, Kaplitt, MG, Fitzsimons, HL, Zuzga, DS, Liu, Y, Oshinsky, ML, et al. Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science 298 (2002), 425–429.
63. 63 Bartus, RT, Weinberg, MS, Samulski, RJ, Parkinson's disease gene therapy: success by design meets failure by efficacy. Mol Ther 22 (2014), 487–497.
64. 64 Decressac, M, Kadkhodaei, B, Mattsson, B, Laguna, A, Perlmann, T, Björklund, A, α-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Sci Transl Med, 4, 2012, 163ra156.
65. 65 Meka, DP, Müller-Rischart, AK, Nidadavolu, P, Mohammadi, B, Motori, E, Ponna, SK, et al. Parkin cooperates with GDNF/RET signaling to prevent dopaminergic neuron degeneration. J Clin Invest 125 (2015), 1873–1885.
66. 66 Cotzias, GC, Van Woert, MH, Schiffer, LM, Aromatic amino acids and modification of parkinsonism. N Engl J Med 276 (1967), 374–379.
67. 67 Cotzias, GC, Papavasiliou, PS, Gellene, R, Modification of Parkinsonism–chronic treatment with L-dopa. N Engl J Med 280 (1969), 337–345.
68. 68 Group, The Deep-Brain Stimulation for Parkinson's Disease Study, Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med 345 (2001), 956–963.
69. 69 Piboolnurak, P, Lang, AE, Lozano, AM, Miyasaki, JM, Saint-Cyr, JA, Poon, YY, et al. Levodopa response in long-term bilateral subthalamic stimulation for Parkinson's disease. Mov Disord 22 (2007), 990–997.
70. 70 Castrioto, A, Lozano, AM, Poon, YY, Lang, AE, Fallis, M, Moro, E, Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Arch Neurol 68 (2011), 1550–1556.
71. 71 Volkmann, J, Albanese, A, Kulisevsky, J, Tornqvist, AL, Houeto, JL, Pidoux, B, et al. Long-term effects of pallidal or subthalamic deep brain stimulation on quality of life in Parkinson's disease. Mov Disord 24 (2009), 1154–1161.
72. 72 Okun, MS, Fernandez, HH, Wu, SS, Kirsch-Darrow, L, Bowers, D, Bova, F, et al. Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trial. Ann Neurol 65 (2009), 586–595.
73. 73 Fasano, A, Daniele, A, Albanese, A, Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation. Lancet Neurol 11 (2012), 429–442.
74. 74 Moro, E, Volkmann, J, König, IR, Winkler, S, Hiller, A, Hassin-Baer, S, et al. Bilateral subthalamic stimulation in Parkin and PINK1 parkinsonism. Neurology 70 (2008), 1186–1191.
75. 75 Leriche, L, Björklund, T, Breysse, N, Besret, L, Grégoire, MC, Carlsson, T, et al. Positron emission tomography imaging demonstrates correlation between behavioral recovery and correction of dopamine neurotransmission after gene therapy. J Neurosci 29 (2009), 1544–1553.
76. 76 Wenning, GK, Odin, P, Morrish, P, Rehncrona, S, Widner, H, Brundin, P, et al. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann Neurol 42 (1997), 95–107.
77. 77 Piccini, P, Brooks, DJ, Björklund, A, Gunn, RN, Grasby, PM, Rimoldi, O, et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci 2 (1999), 1137–1140.
78. 78 Krauss, JK, Pohle, T, Weigel, R, Burgunder, JM, Deep brain stimulation of the centre median-parafascicular complex in patients with movement disorders. J Neurol Neurosurg Psychiatry 72 (2002), 546–548.
79. 79 Plaha, P, Ben-Shlomo, Y, Patel, NK, Gill, SS, Stimulation of the caudal zona incerta is superior to stimulation of the subthalamic nucleus in improving contralateral parkinsonism. Brain 129 (2006), 1732–1747.
80. 80 Plaha, P, Khan, S, Gill, SS, Bilateral stimulation of the caudal zona incerta nucleus for tremor control. J Neurol Neurosurg Psychiatry 79 (2008), 504–513.
81. 81 Alessandro, S, Ceravolo, R, Brusa, L, Pierantozzi, M, Costa, A, Galati, S, et al. Non-motor functions in parkinsonian patients implanted in the pedunculopontine nucleus: focus on sleep and cognitive domains. J Neurol Sci 289 (2010), 44–48.
82. 82 Costa, A, Carlesimo, GA, Caltagirone, C, Mazzone, P, Pierantozzi, M, Stefani, A, et al. Effects of deep brain stimulation of the peduncolopontine area on working memory tasks in patients with Parkinson's disease. Parkinsonism Relat Disord 16 (2010), 64–67.
83. 83 Ferraye, MU, Debû, B, Fraix, V, Goetz, L, Ardouin, C, Yelnik, J, et al. Effects of pedunculopontine nucleus area stimulation on gait disorders in Parkinson's disease. Brain 133 (2010), 205–214.
84. 84 Mazzone, P, Lozano, A, Stanzione, P, Galati, S, Scarnati, E, Peppe, A, et al. Implantation of human pedunculopontine nucleus: a safe and clinically relevant target in Parkinson's disease. Neuroreport 16 (2005), 1877–1881.
85. 85 Mazzone, P, Sposato, S, Insola, A, Scarnati, E, The deep brain stimulation of the pedunculopontine tegmental nucleus: towards a new stereotactic neurosurgery. J Neural Transm (Vienna) 118 (2011), 1431–1451.
86. 86 Plaha, P, Gill, SS, Bilateral deep brain stimulation of the pedunculopontine nucleus for Parkinson's disease. Neuroreport 16 (2005), 1883–1887.
87. 87 Thevathasan, W, Silburn, PA, Brooker, H, Coyne, TJ, Khan, S, Gill, SS, et al. The impact of low-frequency stimulation of the pedunculopontine nucleus region on reaction time in parkinsonism. J Neurol Neurosurg Psychiatry 81 (2010), 1099–1104.
88. 88 Rowland, NC, Starr, PA, Larson, PS, Ostrem, JL, Marks, WJ Jr, Lim, DA, Combining cell transplants or gene therapy with deep brain stimulation for Parkinson's disease. Mov Disord 30 (2015), 190–195.
89. 89 Mie, M, Endoh, T, Yanagida, Y, Kobatake, E, Aizawa, M, Induction of neural differentiation by electrically stimulated gene expression of NeuroD2. J Biotechnol 100 (2003), 231–238.
90. 90 Arias-Carrión, O, Verdugo-Díaz, L, Feria-Velasco, A, Millán-Aldaco, D, Gutiérrez, AA, Hernández-Cruz, A, et al. Neurogenesis in the subventricular zone following transcranial magnetic field stimulation and nigrostriatal lesions. J Neurosci Res 78 (2004), 16–28.
91. 91 Yamada, M, Tanemura, K, Okada, S, Iwanami, A, Nakamura, M, Mizuno, H, et al. Electrical stimulation modulates fate determination of differentiating embryonic stem cells. Stem Cells 25 (2007), 562–570.
92. 92 Chang, KA, Kim, JW, Kim, JA, Lee, SE, Lee, S, Kim, S, et al. Biphasic electrical currents stimulation promotes both proliferation and differentiation of fetal neural stem cells. PLoS One, 6, 2011, e18738.
93. 93 Huang, YJ, Wu, HC, Tai, NH, Wang, TW, Carbon nanotube rope with electrical stimulation promotes the differentiation and maturity of neural stem cells. Small 8 (2012), 2869–2877.
94. 94 Gary, DS, Malone, M, Capestany, P, Houdayer, T, McDonald, JW, Electrical stimulation promotes the survival of oligodendrocytes in mixed cortical cultures. J Neurosci Res 90 (2012), 72–83.
95. 95 Kang, C, Yang, CY, Kim, JH, Moon, SK, Lee, S, Park, SA, et al. The effect of continuous epidural electrical stimulation on neuronal proliferation in cerebral ischemic rats. Ann Rehabil Med 37 (2013), 301–310.
96. 96 Jahanshahi, A, Schonfeld, L, Janssen, ML, Hescham, S, Kocabicak, E, Steinbusch, HW, et al. Electrical stimulation of the motor cortex enhances progenitor cell migration in the adult rat brain. Exp Brain Res 231 (2013), 165–177.
97. 97 Kobelt, LJ, Wilkinson, AE, McCormick, AM, Willits, RK, Leipzig, ND, Short duration electrical stimulation to enhance neurite outgrowth and maturation of adult neural stem progenitor cells. Ann Biomed Eng 42 (2014), 2164–2176.
98. 98 Park, SJ, Park, JS, Yang, HN, Yi, SW, Kim, C-H, Park, K-H, Neurogenesis is induced by electrical stimulation of human mesenchymal stem cells co-cultured with mature neuronal cells. Macromol Biosci, 2015 (epub ahead of print).
99. 99 Stewart, E, Kobayashi, NR, Higgins, MJ, Quigley, AF, Jamali, S, Moulton, SE, et al. Electrical stimulation using conductive polymer polypyrrole promotes differentiation of human neural stem cells: a biocompatible platform for translational neural tissue engineering. Tissue Eng Part C Methods 21 (2015), 385–393.
100. 100 Wang, M, Li, P, Liu, M, Song, W, Wu, Q, Fan, Y, Potential protective effect of biphasic electrical stimulation against growth factor-deprived apoptosis on olfactory bulb neural progenitor cells through the brain-derived neurotrophic factor-phosphatidylinositol 3'-kinase/Akt pathway. Exp Biol Med (Maywood) 238 (2013), 951–959.
101. 101 Toda, H, Hamani, C, Fawcett, AP, Hutchison, WD, Lozano, AM, The regulation of adult rodent hippocampal neurogenesis by deep brain stimulation. J Neurosur 108 (2008), 132–138.
102. 102 Hamani, C, Stone, SS, Garten, A, Lozano, AM, Winocur, G, Memory rescue and enhanced neurogenesis following electrical stimulation of the anterior thalamus in rats treated with corticosterone. Exp Neurol 232 (2011), 100–104.
103. 103 Stone, SS, Teixeira, CM, Devito, LM, Zaslavsky, K, Josselyn, SA, Lozano, AM, et al. Stimulation of entorhinal cortex promotes adult neurogenesis and facilitates spatial memory. J Neurosci 31 (2011), 13469–13484.
104. 104 Schulte, T, Brecht, S, Herdegen, T, Illert, M, Mehdorn, HM, Hamel, W, Induction of immediate early gene expression by high-frequency stimulation of the subthalamic nucleus in rats. Neuroscience 138 (2006), 1377–1385.
105. 105 Henning, J, Koczan, D, Glass, A, Karopka, T, Pahnke, J, Rolfs, A, et al. Deep brain stimulation in a rat model modulates TH, CaMKIIa and Homer1 gene expression. Eur J Neurosci 25 (2007), 239–250.
106. 106 Saryyeva, A, Nakamura, M, Krauss, JK, Schwabe, K, c-Fos expression after deep brain stimulation of the pedunculopontine tegmental nucleus in the rat 6-hydroxydopamine Parkinson model. J Chem Neuroanat 42 (2011), 210–217.
107. 107 Creed, MC, Hamani, C, Nobrega, JN, Early gene mapping after deep brain stimulation in a rat model of tardive dyskinesia: comparison with transient local inactivation. Eur Neuropsychopharmacol 22 (2012), 506–517.
108. 108 Ewing, SG, Porr, B, Pratt, JA, Deep brain stimulation of the mediodorsal thalamic nucleus yields increases in the expression of zif-268 but not c-fos in the frontal cortex. J Chem Neuroanat 52 (2013), 20–24.
109. 109 da Silva, JC, Scorza, FA, Nejm, MB, Cavalheiro, EA, Cukiert, A, c-FOS expression after hippocampal deep brain stimulation in normal rats. Neuromodulation 17 (2014), 213–216.
110. 110 Ho, DX, Tan, YC, Tan, J, Too, HP, Ng, WH, High-frequency stimulation of the globus pallidus interna nucleus modulates GFRα1 gene expression in the basal ganglia. J Clin Neurosci 21 (2014), 657–660.
111. 111 Gondard, E, Chau, HN, Mann, A, Tierney, TS, Hamani, C, Kalia, SK, et al. Rapid modulation of protein expression in the rat hippocampus following deep brain stimulation of the fornix. Brain Stimul 8 (2015), 1058–1064.
112. 112 Selvakumar, T, Alavian, KN, Tierney, T, Analysis of gene expression changes in the rat hippocampus after deep brain stimulation of the anterior thalamic nucleus. J Vis Exp, 2015 (epub ahead of print).
113. 113 Visanji, NP, Kamali Sarvestani, I, Creed, MC, Shams Shoaei, Z, Nobrega, JN, Hamani, C, et al. Deep brain stimulation of the subthalamic nucleus preferentially alters the translational profile of striatopallidal neurons in an animal model of Parkinson's disease. Front Cell Neurosci, 9, 2015, 221.
114. 114 Stefani, A, Lozano, AM, Peppe, A, Stanzione, P, Galati, S, Tropepi, D, et al. Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease. Brain 130 (2007), 1596–1607.
115. 115 Stefani, A, Peppe, A, Pierantozzi, M, Galati, S, Moschella, V, Stanzione, P, et al. Multi-target strategy for Parkinsonian patients: the role of deep brain stimulation in the centromedian-parafascicularis complex. Brain Res Bull 78 (2009), 113–118.
116. 116 Larson, PS, Starr, PA, Bates, G, Tansey, L, Richardson, RM, Martin, AJ, An optimized system for interventional magnetic resonance imaging-guided stereotactic surgery: preliminary evaluation of targeting accuracy. Neurosurgery 70 (2012), 95–103; discussion 103.
117. 117 Ostrem, JL, Galifianakis, NB, Markun, LC, Grace, JK, Martin, AJ, Starr, PA, et al. Clinical outcomes of PD patients having bilateral STN DBS using high-field interventional MR-imaging for lead placement. Clin Neurol Neurosurg 115 (2013), 708–712.
118. 118 Richardson, RM, Kells, AP, Martin, AJ, Larson, PS, Starr, PA, Piferi, PG, et al. Novel platform for MRI-guided convection-enhanced delivery of therapeutics: preclinical validation in nonhuman primate brain. Stereotact Funct Neurosurg 89 (2011), 141–151.